Cargando…

Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates

Susceptible-Exposed-Infected-Removed (SEIR)-type epidemiologic models, modeling unascertained infections latently, can predict unreported cases and deaths assuming perfect testing. We apply a method we developed to account for the high false negative rates of diagnostic RT-PCR tests for detecting an...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattacharyya, Rupam, Kundu, Ritoban, Bhaduri, Ritwik, Ray, Debashree, Beesley, Lauren J., Salvatore, Maxwell, Mukherjee, Bhramar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105357/
https://www.ncbi.nlm.nih.gov/pubmed/33963259
http://dx.doi.org/10.1038/s41598-021-89127-1
_version_ 1783689594065125376
author Bhattacharyya, Rupam
Kundu, Ritoban
Bhaduri, Ritwik
Ray, Debashree
Beesley, Lauren J.
Salvatore, Maxwell
Mukherjee, Bhramar
author_facet Bhattacharyya, Rupam
Kundu, Ritoban
Bhaduri, Ritwik
Ray, Debashree
Beesley, Lauren J.
Salvatore, Maxwell
Mukherjee, Bhramar
author_sort Bhattacharyya, Rupam
collection PubMed
description Susceptible-Exposed-Infected-Removed (SEIR)-type epidemiologic models, modeling unascertained infections latently, can predict unreported cases and deaths assuming perfect testing. We apply a method we developed to account for the high false negative rates of diagnostic RT-PCR tests for detecting an active SARS-CoV-2 infection in a classic SEIR model. The number of unascertained cases and false negatives being unobservable in a real study, population-based serosurveys can help validate model projections. Applying our method to training data from Delhi, India, during March 15–June 30, 2020, we estimate the underreporting factor for cases at 34–53 (deaths: 8–13) on July 10, 2020, largely consistent with the findings of the first round of serosurveys for Delhi (done during June 27–July 10, 2020) with an estimated 22.86% IgG antibody prevalence, yielding estimated underreporting factors of 30–42 for cases. Together, these imply approximately 96–98% cases in Delhi remained unreported (July 10, 2020). Updated calculations using training data during March 15-December 31, 2020 yield estimated underreporting factor for cases at 13–22 (deaths: 3–7) on January 23, 2021, which are again consistent with the latest (fifth) round of serosurveys for Delhi (done during January 15–23, 2021) with an estimated 56.13% IgG antibody prevalence, yielding an estimated range for the underreporting factor for cases at 17–21. Together, these updated estimates imply approximately 92–96% cases in Delhi remained unreported (January 23, 2021). Such model-based estimates, updated with latest data, provide a viable alternative to repeated resource-intensive serosurveys for tracking unreported cases and deaths and gauging the true extent of the pandemic.
format Online
Article
Text
id pubmed-8105357
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81053572021-05-10 Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates Bhattacharyya, Rupam Kundu, Ritoban Bhaduri, Ritwik Ray, Debashree Beesley, Lauren J. Salvatore, Maxwell Mukherjee, Bhramar Sci Rep Article Susceptible-Exposed-Infected-Removed (SEIR)-type epidemiologic models, modeling unascertained infections latently, can predict unreported cases and deaths assuming perfect testing. We apply a method we developed to account for the high false negative rates of diagnostic RT-PCR tests for detecting an active SARS-CoV-2 infection in a classic SEIR model. The number of unascertained cases and false negatives being unobservable in a real study, population-based serosurveys can help validate model projections. Applying our method to training data from Delhi, India, during March 15–June 30, 2020, we estimate the underreporting factor for cases at 34–53 (deaths: 8–13) on July 10, 2020, largely consistent with the findings of the first round of serosurveys for Delhi (done during June 27–July 10, 2020) with an estimated 22.86% IgG antibody prevalence, yielding estimated underreporting factors of 30–42 for cases. Together, these imply approximately 96–98% cases in Delhi remained unreported (July 10, 2020). Updated calculations using training data during March 15-December 31, 2020 yield estimated underreporting factor for cases at 13–22 (deaths: 3–7) on January 23, 2021, which are again consistent with the latest (fifth) round of serosurveys for Delhi (done during January 15–23, 2021) with an estimated 56.13% IgG antibody prevalence, yielding an estimated range for the underreporting factor for cases at 17–21. Together, these updated estimates imply approximately 92–96% cases in Delhi remained unreported (January 23, 2021). Such model-based estimates, updated with latest data, provide a viable alternative to repeated resource-intensive serosurveys for tracking unreported cases and deaths and gauging the true extent of the pandemic. Nature Publishing Group UK 2021-05-07 /pmc/articles/PMC8105357/ /pubmed/33963259 http://dx.doi.org/10.1038/s41598-021-89127-1 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Bhattacharyya, Rupam
Kundu, Ritoban
Bhaduri, Ritwik
Ray, Debashree
Beesley, Lauren J.
Salvatore, Maxwell
Mukherjee, Bhramar
Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates
title Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates
title_full Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates
title_fullStr Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates
title_full_unstemmed Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates
title_short Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates
title_sort incorporating false negative tests in epidemiological models for sars-cov-2 transmission and reconciling with seroprevalence estimates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105357/
https://www.ncbi.nlm.nih.gov/pubmed/33963259
http://dx.doi.org/10.1038/s41598-021-89127-1
work_keys_str_mv AT bhattacharyyarupam incorporatingfalsenegativetestsinepidemiologicalmodelsforsarscov2transmissionandreconcilingwithseroprevalenceestimates
AT kunduritoban incorporatingfalsenegativetestsinepidemiologicalmodelsforsarscov2transmissionandreconcilingwithseroprevalenceestimates
AT bhaduriritwik incorporatingfalsenegativetestsinepidemiologicalmodelsforsarscov2transmissionandreconcilingwithseroprevalenceestimates
AT raydebashree incorporatingfalsenegativetestsinepidemiologicalmodelsforsarscov2transmissionandreconcilingwithseroprevalenceestimates
AT beesleylaurenj incorporatingfalsenegativetestsinepidemiologicalmodelsforsarscov2transmissionandreconcilingwithseroprevalenceestimates
AT salvatoremaxwell incorporatingfalsenegativetestsinepidemiologicalmodelsforsarscov2transmissionandreconcilingwithseroprevalenceestimates
AT mukherjeebhramar incorporatingfalsenegativetestsinepidemiologicalmodelsforsarscov2transmissionandreconcilingwithseroprevalenceestimates